| pubmed-article:2953126 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2953126 | lifeskim:mentions | umls-concept:C0040113 | lld:lifeskim |
| pubmed-article:2953126 | lifeskim:mentions | umls-concept:C0230445 | lld:lifeskim |
| pubmed-article:2953126 | lifeskim:mentions | umls-concept:C1155046 | lld:lifeskim |
| pubmed-article:2953126 | lifeskim:mentions | umls-concept:C0026385 | lld:lifeskim |
| pubmed-article:2953126 | lifeskim:mentions | umls-concept:C0205251 | lld:lifeskim |
| pubmed-article:2953126 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:2953126 | pubmed:issue | 11-12 | lld:pubmed |
| pubmed-article:2953126 | pubmed:dateCreated | 1987-5-22 | lld:pubmed |
| pubmed-article:2953126 | pubmed:abstractText | Endogenous factors preferentially inhibiting T-lymphocyte proliferation were prepared from the acetone precipitate of a 60% ethanol extract from calf thymus and their biochemical properties examined. By ultrafiltration the strongest lymphocyte-selective inhibition was found in the molecular mass range between 1 and 5 kDa. Fast protein liquid chromatography (FPLC) of this fraction on an anion exchange column eluted the lymphocyte inhibitors at 205-265 mM ammonium acetate. Staining procedures following IEF and TLC suggested, that the inhibitors may not be glycoconjugates or amines but small weakly acidic peptides (less than 3 kDa). | lld:pubmed |
| pubmed-article:2953126 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2953126 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2953126 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2953126 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2953126 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2953126 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2953126 | pubmed:issn | 0939-5075 | lld:pubmed |
| pubmed-article:2953126 | pubmed:author | pubmed-author:MaurerH RHR | lld:pubmed |
| pubmed-article:2953126 | pubmed:author | pubmed-author:MatthiessenH... | lld:pubmed |
| pubmed-article:2953126 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2953126 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:2953126 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2953126 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2953126 | pubmed:pagination | 1131-6 | lld:pubmed |
| pubmed-article:2953126 | pubmed:dateRevised | 2009-11-4 | lld:pubmed |
| pubmed-article:2953126 | pubmed:meshHeading | pubmed-meshheading:2953126-... | lld:pubmed |
| pubmed-article:2953126 | pubmed:meshHeading | pubmed-meshheading:2953126-... | lld:pubmed |
| pubmed-article:2953126 | pubmed:meshHeading | pubmed-meshheading:2953126-... | lld:pubmed |
| pubmed-article:2953126 | pubmed:meshHeading | pubmed-meshheading:2953126-... | lld:pubmed |
| pubmed-article:2953126 | pubmed:meshHeading | pubmed-meshheading:2953126-... | lld:pubmed |
| pubmed-article:2953126 | pubmed:meshHeading | pubmed-meshheading:2953126-... | lld:pubmed |
| pubmed-article:2953126 | pubmed:meshHeading | pubmed-meshheading:2953126-... | lld:pubmed |
| pubmed-article:2953126 | pubmed:meshHeading | pubmed-meshheading:2953126-... | lld:pubmed |
| pubmed-article:2953126 | pubmed:meshHeading | pubmed-meshheading:2953126-... | lld:pubmed |
| pubmed-article:2953126 | pubmed:articleTitle | Low molecular mass inhibitors from calf thymus selective for T-lymphocyte proliferation. | lld:pubmed |
| pubmed-article:2953126 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2953126 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
